More tools:Markets·Screener·Research·Chat

Cartesian Therapeutics, Inc. Common Stock (RNAC) Financial Statements

Cartesian Therapeutics, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001V0FQQ0
XNAS · usd
8.69▼ 0.26 (-2.91%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close8.95
Day's Range8.56 – 9.15
52-Week Range5.60 – 11.00
Volume94.2K
Avg Volume119.2K
Share Statistics
Shares Outstanding
Employees75
ExchangeXNAS
Listed2016-06-22
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Cartesian Therapeutics, Inc. Common Stock (RNAC)
What is Cartesian Therapeutics, Inc. Common Stock's Market Cap?
Cartesian Therapeutics, Inc. Common Stock's Market Cap is $262.9M, based on as-reported figures from SEC (XBRL) filings.
What is Cartesian Therapeutics, Inc. Common Stock's Enterprise Value?
Cartesian Therapeutics, Inc. Common Stock's Enterprise Value is $168.2M, based on as-reported figures from SEC (XBRL) filings.
What is Cartesian Therapeutics, Inc. Common Stock's Price / Sales?
Cartesian Therapeutics, Inc. Common Stock's Price / Sales is 178.0×, based on as-reported figures from SEC (XBRL) filings.
What is Cartesian Therapeutics, Inc. Common Stock's EV / Revenue?
Cartesian Therapeutics, Inc. Common Stock's EV / Revenue is 113.9×, based on as-reported figures from SEC (XBRL) filings.
What is Cartesian Therapeutics, Inc. Common Stock's EV / EBITDA?
Cartesian Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Cartesian Therapeutics, Inc. Common Stock's Revenue (TTM)?
Cartesian Therapeutics, Inc. Common Stock's Revenue (TTM) is $1.5M, based on as-reported figures from SEC (XBRL) filings.
What is Cartesian Therapeutics, Inc. Common Stock's Net Income (TTM)?
Cartesian Therapeutics, Inc. Common Stock's Net Income (TTM) is -$151.9M, based on as-reported figures from SEC (XBRL) filings.
What is Cartesian Therapeutics, Inc. Common Stock's EBITDA?
Cartesian Therapeutics, Inc. Common Stock's EBITDA is -$152.8M, based on as-reported figures from SEC (XBRL) filings.
What is Cartesian Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Cartesian Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -5.02, based on as-reported figures from SEC (XBRL) filings.
What is Cartesian Therapeutics, Inc. Common Stock's EBITDA Margin?
Cartesian Therapeutics, Inc. Common Stock's EBITDA Margin is -10342.5%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Collaboration and license—
YoY growth——+100.0%—
Grant—
Total revenues—
Operating expenses:
Research and development—
General and administrative—
Total operating expenses—
% of revenue————
Operating loss—
% of revenue————
Other income (expense):
Interest income—
Interest expense———
(Loss) gain on change in fair value of warrant liability—
Loss on change in fair value of embedded derivative———
Gain on change in fair value of contingent value rights liability—
Other income (expense), net—
Total other income, net———
Net income (loss)
% of revenue————
Net income (loss)——
Less: Undistributed earnings allocable to participating securities, basic———
Net income (loss) allocable to shares of common stock - basic———
Net income (loss)——
Less: Undistributed earnings allocable to participating securities, diluted———
Net income (loss) allocable to shares of common stock - diluted———
Basic (in dollars per share)——
Diluted (in dollars per share)——